公开(公告)号：EP2809672A4

公开(公告)日：2015-11-25

申请号：EP13743025

申请日：2013-01-30

Applicant: PHARMACYCLICS INC

Inventor： YAN SHUNQI ,  WANG LONGCHENG ,  FRYE LEAH LYNN ,  CHEN WEI ,  LOURY DAVID J

IPC: C07D473/32 ,  A61K31/52 ,  A61P35/00 ,  A61P37/00

CPC classification number: C07D473/34

公开(公告)号：HK1203489A1

公开(公告)日：2015-10-30

申请号：HK15103865

申请日：2015-04-21

Applicant: PHARMACYCLICS INC

Inventor： CHEN WEI ,  LOURY DAVID J ,  YAN SHUNQI ,  WANG LONGCHENG ,  FRYE LEAH LYNN

IPC: C07D20060101 ,  A61K20060101 ,  A61P20060101

公开(公告)号：CA2863140C

公开(公告)日：2016-10-18

申请号：CA2863140

申请日：2013-01-30

Applicant: PHARMACYCLICS INC

Inventor： YAN SHUNQI ,  WANG LONGCHENG ,  FRYE LEAH LYNN ,  CHEN WEI ,  LOURY DAVID J

IPC: C07D473/34 ,  A61K31/522 ,  A61P37/06

Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

公开(公告)号：MX2014009219A

公开(公告)日：2015-02-05

申请号：MX2014009219

申请日：2013-01-30

Applicant: PHARMACYCLICS INC

Inventor： YAN SHUNQI ,  CHEN WEI ,  LOURY DAVID J ,  WANG LONGCHENG ,  FRYE LEAH LYNN

IPC: C07D473/32 ,  A61K31/52 ,  A61P35/00 ,  A61P37/00

Abstract: Se describen en el presente documento compuestos que forman enlaces covalentes con la tirosina quinasa de Bruton (Btk). También se describen inhibidores irreversibles de Btk. Además, también se describen inhibidores reversibles de Btk. También se describen composiciones farmacéuticas que incluyen los compuestos. Se describen métodos para utilizar los inhibidores de Bkt, solos junto con otros agentes terapéuticos, para el tratamiento de dolencias o enfermedades autoinmunes, enfermedades o dolencias heteroinmunes, cáncer, incluyendo linfoma, y enfermedades o dolencias inflamatorias.

公开(公告)号：CA2863140A1

公开(公告)日：2013-08-08

申请号：CA2863140

申请日：2013-01-30

Applicant: PHARMACYCLICS INC

Inventor： YAN SHUNQI ,  WANG LONGCHENG ,  FRYE LEAH LYNN ,  CHEN WEI ,  LOURY DAVID J

IPC: C07D473/32 ,  A61K31/52 ,  A61P35/00 ,  A61P37/00

Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

公开(公告)号：PH12014501815B1

公开(公告)日：2014-11-17

申请号：PH12014501815

申请日：2014-07-31

Applicant: PHARMACYCLICS INC

Inventor： CHEN WEI ,  LOURY DAVID J ,  YAN SHUNQI ,  WANG LONGCHENG ,  FRYE LEAH LYNN

IPC: A61K31/52 ,  A61P35/00 ,  A61P37/00 ,  C07D473/32

Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

公开(公告)号：AU2013215166A1

公开(公告)日：2014-08-28

申请号：AU2013215166

申请日：2013-01-30

Applicant: PHARMACYCLICS INC

Inventor： CHEN WEI ,  LOURY DAVID J ,  YAN SHUNQI ,  WANG LONGCHENG ,  FRYE LEAH LYNN

IPC: C07D473/32 ,  A61K31/52 ,  A61P35/00 ,  A61P37/00

Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.